Exenatide and Metformin Therapy in Overweight Women With PCOS
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Current research has shown that the use of diabetes management practices aimed at reducing
insulin resistance and hyperinsulinemia (such as weight reduction and the administration of
oral antidiabetic drugs) in women with PCOS can not only improve glucose and lipid metabolism
but can also reverse testosterone abnormalities and restore menstrual cycles. A new medicine
called exenatide (Byetta) has been found to reduce body weight, as well as, improve abnormal
glucose metabolism in diabetics. This randomized study will compare Exenatide (Byetta) to
extended release metformin (Fortamet) to combination therapy (both Byetta and Fortamet) on
menstrual cyclicity, hormone profiles and metabolic profiles over a 24-week period in women
with PCOS.